2019 Summit Speakers

Samuel J. Asirvatham, M.D.
Professor of Medicine and Pediatrics; Division of Pediatric Cardiology and Department of Physiology and Biomedical Engineering; Program Director, Electrophysiology Fellowship Program, Mayo Clinic College of Medicine
Samuel J. Asirvatham, M.D., is a cardiac electrophysiology consultant in the Division of Heart Rhythm Services, Department of Cardiovascular Medicine at Mayo Clinic in Rochester, Minnesota. Dr. Asirvatham holds joint appointments in the Division of Pediatric Cardiology and the Department of Physiology and Biomedical Engineering. In addition, he serves as vice chair for innovation in the Department of Cardiovascular Medicine, where he is also medical director of the Electrophysiology Laboratory. He holds the academic rank of professor of medicine and pediatrics in Mayo Clinic College of Medicine and Science.

Ehrin Armstrong, M.D.
Associate Professor, Medicine-Cardiology; Director, Interventional Cardiology; Co-Director, Vascular Laboratory, VA Eastern Colorado Healthcare System
Interventional Cardiology, Cardiology, Cardiovascular Disease, Internal Medicine, Heart and Circulation, Heart and Circulation - Heart Diseases, Heart and Circulation - Circulatory Disorders, Heart and Circulation - Peripheral Artery Disease, Heart and Circulation - Interventional Cardiology, Heart and Circulation - Heart Attack, Heart and Circulation - Coronary Disease, Heart and Circulation - Angioplasty, Heart and Circulation – Aneurysms.



Deepak L. Bhatt, M.D., MPH, FACC, FAHA, FSCAI, FESC
Professor of Medicine, Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart & Vascular Center, Harvard Medical School
Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at the Massachusetts Institute of Technology while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University and a Master in Public Health with a concentration in clinical effectiveness from Harvard University. His internship and residency in internal medicine were at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship, Associate Director of the Cardiovascular Medicine Fellowship, and Associate Director of the Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System and served in that role for several years. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar.

Alan Chait, M.D.
Edwin L. Bierman Professor of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington
Edwin L. Bierman Professor of Medicine at the University of Washington in Seattle, where he was Head of the Division of Metabolism, Endocrinology and Nutrition from 1996-2016. He obtained his MBChB (MD equivalent) and MD (PhD equivalent) from the University of Cape Town in South Africa.  After internship at the Groote Schuur Hospital in Cape Town, he did residency equivalence and postgraduate training, including a fellowship in Lipid Research at the Royal Postgraduate Medical School in London, after which he was a Lecturer in Endocrinology at the London Hospital Medical School.  He came to the US in 1975 for a fellowship in Endocrinology and Metabolism at the University of Washington, after which he remained on the faculty and progressed through the ranks, being appointed Professor of Medicine in 1985.

He has extensive research experience, having published numerous papers related mainly to lipids, lipoproteins, diabetes and cardiovascular disease.  He directed the UW’s He directed the UW’s Nutrition Obesity Research Center (previously known as the Clinical Nutrition Research Unit) from 1992-2012, is director of the UW Lipid Clinic at Harborview Medical Center and is past chair of the American Heart Association Nutrition Committee

Joaquin Cigarroa, M.D.
Head of the Division of Cardiovascular Medicine; Clinical Chief of Knight Cardiovascular Institute; Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University
Dr Joaquin E. Cigarroa came to OHSU in January of 2006 from the University of Texas Southwestern Medical School, where he was an Associate Professor of Medicine, and the Director of Interventional Cardiology and the recipient of the Rappoport Distinguished Professor.
He was raised in South Texas and received his undergraduate degree from Yale, medical degree from Cornell and his postgraduate training internal medicine, cardiology and interventional cardiology at the Massachusetts General Hospital.

Since arriving at OHSU, Dr Cigarroa has served as the Associate Chief of Clinical Affairs for the division of cardiology and now for the Knight Cardiovascular Institute. He continues to work clinically, with a specific focus on complex coronary interventions and structural heart disease. He has a longstanding interest in valvular heart disease, hypertrophic cardiomyopathy and performs procedures in all aspects of structural heart disease.

Maros Ferencik, M.D., Ph.D.
Associate Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University
Focuses his research on the effective and efficient use of cardiac CT in the assessment of coronary atherosclerosis and coronary artery disease. He studies coronary atherosclerotic plaques and looks for morphologic plaque features associated with high-risk (vulnerable plaques). His research addresses several important questions such as whether novel CT technology allows detection of late enhancement and other coronary plaque features that correlate with high-risk plaques in OCT and culprit lesions of ACS and whether these features improve the diagnostic accuracy of CT for the diagnosis of ACS and prognosis of future cardiovascular events in large multicenter clinical trials (ROMICAT II and PROMISE). The epidemiologic component of this research will assess the predictive value of novel measures of coronary calcium for cardiovascular events in primary prevention in the Framingham Heart Study population.

Satya (Tom) Sarma, M.D.
Assistant Professor of Internal Medicine, UT Southwestern Medical Center
Dr. Sarma became interested in cardiovascular diseases during his undergraduate studies in engineering. He went on to pursue medical training at Boston University where he also served as Chief Medical Resident. Interested in molecular biology research, he then worked at Baylor Medical College as a post-doctoral fellow in the Department of Biophysics and Molecular Physiology, focusing on abnormalities in cardiac ryanodine receptor function. After two years of research fellowship, he went on to complete a clinical cardiology fellowship at Northwestern University where he was selected as Chief Cardiology Fellow during his second year. He is interested in heart failure with preserved ejection fraction, a type of heart failure common in seniors, and came to UT Southwestern in 2012 to study new treatment options for patients with this common but difficult to treat condition. He also has an interest in metabolic disorders, specifically diabetes and insulin resistance, and his clinical practice focuses on exercise training programs to improve patient symptoms and quality of life.

Stephen Heitner, M.D.
Associate Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University
Dr. Heitner specializes in caring for patients with uncommon and complex cardiac conditions. He has developed an the interest and skills necessary to assist him in making the careful decisions with patients and their families that will help improve and prolong lives. He realizes that hypertrophic cardiomyopathy is a condition that affects not only the patient, but also potentially their parents, children, siblings, and extended family. As such, each patient is approached from a fresh perspective and a thoughtful treatment plan is devised.

Dr. Heitner cares for many patients with cardiac amyloidosis in conjunction with a medical oncologist. Together they have helped patients through the difficult time of chemotherapy and stem cell transplantation with excellent results.

Dr. Heitner is also an expert in cardiac imaging, and has implemented the latest developments in cardiac ultrasound technology in to the echocardiography laboratory at OHSU. Through the use of contrast echocardiography, 3D echocardiography, and even newer promising technologies, Dr. Heitner is helping improve the detection of disease, as well as guide non-surgical repair of structural cardiac problems (e.g. transcutaneous valve replacements, septal defect repairs)

Judith Hochman, M.D.
Professor of Cardiology; Associate Director, Division of Cardiology, Department of Medicine; Senior Associate Dean for Clinical Sciences; Director, Cardiovascular Clinical Research Center, NYU Langone Health
Dr. Judith Hochman is Senior Associate Dean for Clinical Sciences, Co-Director, NYU-HHC Clinical and Translational Science Institute, Professor and Associate Director of Cardiology at NYU Langone Health.

She is an internationally recognized clinical trialist and expert in ischemic heart disease. She has chaired NHLBI-funded international clinical trials testing the role of revascularization in ischemic heart disease which led to new recommendations in the US and International Practice Guidelines. She co-directs the American Heart Association (AHA)-funded Soter Center for Women’s Cardiovascular Research.Dr. Hochman has served as mentor for numerous trainees who have gone on to have successful independent careers. She is the recipient of 2008 AHA Women in Cardiology Mentoring Award, 2014 AHA Clinical Research Prize, 2016 American College of Cardiology Distinguished Scientist Award, and the AHA 2018 James B. Herrick Award for Outstanding Achievement in Clinical Cardiology.

Mikhail Kosiborod, M.D.
Professor of Medicine, University of Missouri-Kansas City School of Medicine, St. Luke’s Health System
Dr. Mikhail Kosiborod is a cardiologist, Vice President of Research at Saint Luke’s Health System, Director of Cardiometabolic Research and the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. He received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine. Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. He has authored and co-authored over 180 peer-reviewed publications, including scientific statements and position documents. He is involved in the leadership of numerous clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multi-center trials in diabetes and cardiovascular disease.

Michael Mack, M.D., F.A.C.C.
Medical Director, Cardiovascular Surgery, Baylor Health Care System; Chairman of Baylor Scott & White The Heart Hospital, Plano Research Center
Michael Mack, M.D. has practiced cardiothoracic surgery in Dallas, TX since 1982.  He is board certified in Internal Medicine, General Surgery, and Thoracic Surgery and is currently the Director of the Cardiovascular Service Line for the Baylor Scott & White Health, Chair of the Baylor Scott & White Cardiovascular Governance Council and Director of Cardiovascular Research at The Heart Hospital Baylor Plano. He also co-founded the Cardiopulmonary Research Science and Technology Institute (CRSTI). He has over 650 peer reviewed publications.

He is on the Steering Committee of the Cardiothoracic Surgery Network (CTSN) of the NIH and is a member of the American College of Cardiology Foundation (ACCF) Board of Trustees, the ACC Governance Committee, ACC Innovations Work Group and is the Co-Chair of the STS/ACC National Transcatheter Valve Therapy (TVT) Registry Stakeholder Advisory Group. He is a member of the FDA MDEpiNet Advisory Committee. He is currently a Director of the American Board of Thoracic Surgery and was a member of the National Medical Device Planning Board of the FDA/Duke Margolis Institute.

Dr. Mack was President of the Society of Thoracic Surgeons (STS) 2011 and is Past President of the Thoracic Surgery Foundation for Research and Education (TSFRE) 2009-2011, the Southern Thoracic Surgical Association (STSA) 2009 and the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2000.
He is an honorary member of the German Society for Thoracic and Cardiovascular Surgery and the Indian Association of Cardiovascular and Thoracic Surgery and has received the Presidential Citation of the American College of Cardiology and the Transcatheter Cardiovascular Therapeutics (TCT) Lifetime Achievement Award.

Melvin Scheinman, M.D.
Professor of Medicine, Walter H. Shorenstein Endowed Chair in Cardiology, Chief of Cardiology Genetrics Arrhythmia Program
Dr. Melvin Scheinman received his undergraduate degree at Johns Hopkins and medical degree at the Albert Einstein College of Medicine.  He received his postgraduate training in Cardiology at UCSF and established the Cardiac Electrophysiology section at UCSF in 1979.  He was the first to apply catheter ablation in humans and was instrumental in in defining mechanisms of arrhythmias as well as ablative procedures for complex arrhythmias.

He currently holds the Shorenstein chair in Cardiology and is director of the Comprehensive Genetic Arrhythmia section at UCSF.  He has received a number of pioneer and outstanding teaching awards from the ACC, Heart Rhythm society as well as UCSF.  In 2014, he was awarded the outstanding scientist award (clinical domain) from the American College of Cardiology.

Firas Zahr, M.D.
Associate Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine; Director of Interventional Cardiology; Co-Director of Complex Heart Valve Program, Oregon Health & Science University
Expertise is in Vascular Medicine with a Special focus on Cardiac Catheterization, General Cardiology, Heart Valve, and Interventional Cardiology
I love to get to know the patients and families well so that I can provide appropriate care and meet their expectations. I believe that cardiologists in academic centers should able to deliver tomorrow’s therapy to our sick patients today with excellent outcomes. I am passionate about treating complex heart and valve disease patients with minimally invasive approach or without open heart surgery. In my leisure time, I enjoy spending time with my family experiencing the outdoors.